Journal
JOURNAL OF HOSPITAL INFECTION
Volume 107, Issue -, Pages 35-39Publisher
W B SAUNDERS CO LTD
DOI: 10.1016/j.jhin.2020.09.035
Keywords
COVID-19; SARS-CoV-2; Rapid diagnostics
Funding
- Agency for Healthcare Research and Quality Connected Emergency Care Patient Safety Learning Lab [R18 HS26640]
- Biomedical Advanced Research and Development Authority BARDA [IDSEP150023-01-00]
- Centers for Disease Control, Modeling in Infectious Disease Network [U01CK000536]
- National Institute of Allergy and Infectious Diseases [HHSN272201400007C]
Ask authors/readers for more resources
Rapid molecular testing for SARS-CoV-2 can significantly reduce the time to diagnosis of COVID-19, decrease healthcare-related exposure, conserve infection control resources, and increase treatment capacity.
Opportunity exists to decrease healthcare-related exposure to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), preserve infection control resources, and increase care capacity by reducing the time to diagnosis of coronavirus disease 2019 (COVID-19). A retrospective cohort analysis was undertaken to measure the effect of targeted rapid molecular testing for SARS-CoV-2 on these outcomes. In comparison with standard platform testing, rapid testing was associated with a 65.6% reduction (12.6 h) in the median time to removal from the isolation cohort for patients with negative diagnostic results. This translated to an increase in COVID-19 treatment capacity of 3028 bed-hours and 7500 fewer patient interactions that required the use of personal protective equipment per week. (C) 2020 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available